We treated GC-resistant Reh and Jurkat ALL cell lines with different concentrations (1 or 5 μmol/l) of the Bcl-2 inhibitor ABT-263, dexamethasone, or dexamethasone plus ABT-263. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.